Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Down 65.3% in December

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 43,700 shares, a decrease of 65.3% from the November 30th total of 125,800 shares. Approximately 0.5% of the company’s stock are short sold. Based on an average daily volume of 1,060,000 shares, the days-to-cover ratio is currently 0.0 days.

Revelation Biosciences Trading Down 0.5 %

NASDAQ REVB traded down $0.00 during mid-day trading on Friday, hitting $0.35. The company’s stock had a trading volume of 711,196 shares, compared to its average volume of 956,247. The firm has a market capitalization of $1.50 million, a price-to-earnings ratio of -0.02 and a beta of 0.15. The company’s 50 day simple moving average is $0.67 and its 200 day simple moving average is $1.11. Revelation Biosciences has a twelve month low of $0.28 and a twelve month high of $25.26.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.